Supernus Pharmaceuticals Statistics
Share Statistics
Supernus Pharmaceuticals has 55.99M
shares outstanding. The number of shares has increased by 1.53%
in one year.
| Shares Outstanding | 55.99M |
| Shares Change (YoY) | 1.53% |
| Shares Change (QoQ) | 1.08% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 69 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 4.18M, so 7.48% of the outstanding
shares have been sold short.
| Short Interest | 4.18M |
| Short % of Shares Out | 7.48% |
| Short % of Float | 11.32% |
| Short Ratio (days to cover) | 8.69 |
Valuation Ratios
The PE ratio is 26.97 and the forward
PE ratio is 12.75.
Supernus Pharmaceuticals's PEG ratio is
0.
| PE Ratio | 26.97 |
| Forward PE | 12.75 |
| PS Ratio | 3.01 |
| Forward PS | 2 |
| PB Ratio | 1.92 |
| P/FCF Ratio | 11.64 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Supernus Pharmaceuticals has an Enterprise Value (EV) of 1.96B.
| EV / Sales | 2.96 |
| EV / EBITDA | 10.98 |
| EV / EBIT | 11.38 |
| EV / FCF | 11.43 |
Financial Position
The company has a current ratio of 2.35,
with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.35 |
| Quick Ratio | 2.16 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.19 |
| Debt / FCF | 0.2 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 7.13% and Return on Invested Capital is 5.69%.
| Return on Equity | 7.13% |
| Return on Assets | 5.4% |
| Return on Invested Capital | 5.69% |
| Revenue Per Employee | $981,924.33 |
| Profits Per Employee | $109,591.99 |
| Employee Count | 674 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 1.43 |
Taxes
| Income Tax | 24M |
| Effective Tax Rate | 24.53% |
Stock Price Statistics
The stock price has increased by 15.37% in the
last 52 weeks. The beta is 0.71, so Supernus Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.71 |
| 52-Week Price Change | 15.37% |
| 50-Day Moving Average | 32.03 |
| 200-Day Moving Average | 34.22 |
| Relative Strength Index (RSI) | 50.62 |
| Average Volume (20 Days) | 555,433 |
Income Statement
In the last 12 months, Supernus Pharmaceuticals had revenue of 661.82M
and earned 73.86M
in profits. Earnings per share was 1.34.
| Revenue | 661.82M |
| Gross Profit | 583.91M |
| Operating Income | 81.67M |
| Net Income | 73.86M |
| EBITDA | 178.28M |
| EBIT | 97.87M |
| Earnings Per Share (EPS) | 1.34 |
Full Income StatementBalance Sheet
The company has 69.33M in cash and 34.27M in
debt, giving a net cash position of 35.06M.
| Cash & Cash Equivalents | 69.33M |
| Total Debt | 34.27M |
| Net Cash | 35.06M |
| Retained Earnings | 556.43M |
| Total Assets | 1.35B |
| Working Capital | 405.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 171.95M
and capital expenditures -725K, giving a free cash flow of 171.23M.
| Operating Cash Flow | 171.95M |
| Capital Expenditures | -725K |
| Free Cash Flow | 171.23M |
| FCF Per Share | 3.11 |
Full Cash Flow StatementMargins
Gross margin is 88.23%, with operating and profit margins of 12.34% and 11.16%.
| Gross Margin | 88.23% |
| Operating Margin | 12.34% |
| Pretax Margin | 14.79% |
| Profit Margin | 11.16% |
| EBITDA Margin | 26.94% |
| EBIT Margin | 12.34% |
| FCF Margin | 25.87% |
